EMVision Medical Devices (ASX:EMV) said seven hospitals, including two trial locations in Australia and four in the US, are enrolling patients for the validation trial for the emu point-of-care brain scanner, according to a Tuesday Australian bourse filing.

Several patients were recruited and scanned at each site as part of training verification. Feedback from users and the evaluation of training verification data led to the development of a software feature that will provide users with real-time feedback on scan quality at the point of acquisition. This feature is being tested in-house ahead of integration into emu devices.

At the request of two participating trial sites, additional emu devices were shipped to support the activation of additional hospital network sites within the New York-based Mt Sinai and Houston-based Memorial Hermann healthcare systems.